Reply Named a Visionary in the 2025 Gartner ® Magic Quadrant™ for Warehouse Management Systems

20.5.2025 10:00:00 CEST | Business Wire | Press Release

Reply, a global systems integrator and consulting firm, has been recognized for the sixth consecutive year as a Visionary in the 2025 Gartner^® Magic Quadrant™ for Warehouse Management Systems (WMS). We believe that this acknowledgment reflects Reply’s continued commitment to delivering a cutting-edge, AI-powered warehouse management solution that enables global enterprises to digitize and optimize their supply chain operations. The evaluation was based on Reply’s ability to execute and its completeness of vision.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520066764/en/

LEA Reply™ is Reply’s next-generation digital supply chain platform, designed to meet the evolving demands of modern logistics. Built on a modular, cloud-native, and microservices-based architecture, LEA Reply™ offers flexibility and scalability—empowering clients to rapidly adapt and innovate across their supply chain operations.

At the core of the platform, LEA Reply™ WMSoptimizes warehouse management by streamlining workflows, enhancing visibility, and driving operational efficiency. From inbound to outbound, the solution enables real-time coordination and intelligent automation at every step of the process, from automated put-away strategies tailored to product rotation, to dynamic picking methods such as cluster picking and wave picking, already implemented at leading retailers and 3PLs. LEA Reply™ WMS also supports live inventory updates and seamless integration with automated material handling equipment, enabling clients to reduce stock discrepancies and cut dock-to-stock time.

Taking it a step further, the platform is augmented by GaliLEA, Reply’s generative AI-powered multi-agent assistant. GaliLEA is a flexible, scalable platform designed to evolve alongside your business. Built on a modular architecture, it allows for the seamless integration of the AI capabilities needed today, with the ability to expand as operations grow. Natively integrated with LEA Reply™, GaliLEA enhances usability and efficiency in warehouse management through intuitive conversational AI and leverages a set of specialized AI agents that handle distinct tasks: “Smart Search” retrieves inventory and operations data via voice, “Smart Support” provides contextual, voice-driven answers for faster issue resolution, “Ticket Helper” auto-generates support tickets to streamline responses, and “Dashboarder” enables the creation of customized dashboards and reports through voice commands.

“We are proud to be recognized by Gartner as a Visionary,” said Enrico Nebuloni, Executive Partner at Reply. “For us, this acknowledgment reinforces our vision to transform warehouse management into an intelligent, adaptive platform that learns from operational data and real-world contexts. With GaliLEA, we are building an ecosystem of AI agents that go beyond automation—they orchestrate complex logistics decisions in real time and unlock new value models based on usage and scalability. LEA is no longer just a configurable WMS; it’s becoming a living system, capable of evolving and learning for our clients.”

Gartner, Magic Quadrant for Warehouse Management Systems, Dwight Klappich, Simon Tunstall, Rishabh Narang, Federica Stufano 1 May 2025

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply supports major European industrial groups in the telecom and media; industry and services; banking and insurance and public sectors in defining and developing business models enabled by the new paradigms of AI, cloud computing, digital media and the internet of things. Reply's services include: consulting, system integration and digital services. www.reply.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250520066764/en/

Contacts

Press contact:

Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Irene Caia
i.caia@reply.com
Tel. +39 02 535761

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom